Triumeq Pd Kit
NDC Package 49702-258-37

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Triumeq Pd (abacavir sulfate, dolutegravir sodium, lamivudine) kits is tRIUMEQ is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients weighing at least 40 kg.Limitations of Use:•TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegravir in TRIUMEQ is insufficient in these subpopulations. This formulation utilizes a kit delivery system. Marketed by Viiv Healthcare Company, this product is identified by NDC 49702-258 and is authorized under FDA application NDA215413.

Identification & Billing

NDC Package Code
49702-258-37
Package Description
1 KIT in 1 CARTON * 90 TABLET, FILM COATED in 1 BOTTLE (49702-272-59)
Product Code
49702-258
11-Digit Billing Format
49702025837
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
RxNorm Crosswalk
  • RxCUI: 1546888 - abacavir 600 MG / dolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet
  • RxCUI: 1546888 - abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet
  • RxCUI: 1546888 - abacavir 600 MG / dolutegravir 50 MG / 3TC 300 MG Oral Tablet
  • RxCUI: 1546894 - Triumeq 600 MG / 50 MG / 300 MG Oral Tablet
  • RxCUI: 1546894 - abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Triumeq]

Clinical Specifications

Proprietary Name
Triumeq Pd
Non-Proprietary Name
Abacavir Sulfate, Dolutegravir Sodium, Lamivudine
Dosage Form
Kit - A packaged collection of related material.
Usage Information
TRIUMEQ is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients weighing at least 40 kg.Limitations of Use:•TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegravir in TRIUMEQ is insufficient in these subpopulations. See full prescribing information for TIVICAY (dolutegravir).

Regulatory & Marketing

Labeler Name
Viiv Healthcare Company
Product Type
Human Prescription Drug
FDA Application #
NDA215413
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-30-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49702-258-37 identifies a specific commercial package of 1 kit in 1 carton * 90 tablet, film coated in 1 bottle (49702-272-59) of Triumeq Pd, a human prescription drug labeled by Viiv Healthcare Company. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Viiv Healthcare Company on March 30, 2022. The current certification is valid through December 31, 2027.

How is this Viiv Healthcare Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49702025837. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49702-258-37
11-Digit CMS (5-4-2)
49702-0258-37

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.